Market Overview:
The global nucleic acid vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of infectious diseases, rising demand for preventive vaccines, and technological advancements in nucleic acid vaccine development. Based on type, the global nucleic acid vaccine market is segmented into preventive nucleic acid vaccines and therapeutic nucleic acid vaccines. The preventive segment is further sub-segmented into prophylactic and pre-exposure prophylaxis (PREP) vaccines. The therapeutic segment is further sub-segmented into cancer therapy and other therapies. Based on application, the global nucleic acid vaccine market is divided into hospitals, clinics, and others segments. Geographically, the global nucleic acid vaccine market is analyzed across North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U K), Asia Pacific (Japan China India Australia South Korea Taiwan Thailand Malaysia Indonesia Philippines Vietnam Singapore Sri Lanka Maldives), Middle East & Africa (South Africa Saudi Arabia UAE Qatar Bahrain Kuwait Oman).
Product Definition:
A nucleic acid vaccine is a vaccine that uses pieces of DNA or RNA to help the body build immunity to disease. These vaccines can be made from viruses, bacteria, or parasites. They work by introducing a small amount of the organism's genetic material into the body.
Preventive Nucleic Acid Vaccine:
Preventive nucleic acid vaccine is a new type of vaccine which prevents against disease rather than making the body immune to an infection already present in it. The mechanism of action for preventive nucleic acid vaccines works through the recognition of a particular virus or bacteria by the immune system before it causes harm.
Therapeutic Vucleic Acid Vaccine:
Therapeutic Vucleic Acid Vaccine (TTV) is a new term in the field of vaccinology. It refers to an attenuated virus, which is used for treatment and prevention of diseases. The vaccine consists of DNA or RNA extracted from the causative agent, which helps in stimulating the body’s immune system to fight against disease-causing agents.
Application Insights:
The hospital segment dominated the global market in 2017. This can be attributed to factors such as increasing prevalence of chronic diseases, growing geriatric population and rising number of cancer cases. According to WHO, around 1 in 6 people dies from cancer. In addition, according to the American Cancer Society more than 200,000 people die from this disease worldwide every year and it is expected that around half of these deaths will occur in developing countries by 2030 due to increase in life expectancy and crude birth rate over the forecast period. Thus, increasing incidence of cancer across the globe is boosting product demand at a significant level within hospital setting only which may hinder growth outside this segment eventually.
The others application segment includes clinics.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high investment in research & development, and rising incidence of infectious diseases. Moreover, increasing demand for preventive vaccines is also expected to drive this regional market over the forecast period.
Asia Pacific is anticipated to witness significant growth during the forecast period owing to growing target population base and rising awareness about new vaccination technologies among healthcare professionals & patients.
Growth Factors:
- Increasing demand for prophylactic and therapeutic vaccines
- Growing prevalence of infectious diseases
- Technological advancements in vaccine development and production processes
- Rising public awareness about the benefits of vaccination
- Growing investments by pharmaceutical companies in the nucleic acid vaccine market
Scope Of The Report
Report Attributes
Report Details
Report Title
Nucleic Acid Vaccine Market Research Report
By Type
Preventive Nucleic Acid Vaccine, Therapeutic Vucleic Acid Vaccine
By Application
Hospital, Clinic, Others
By Companies
Moderna, CureVac, Inovio, Sanofi, GSK, CNBG, Hualan Bio, Zhifei Shengwu, Liaoning Chengda, BioKangtai, CanSinoBIO, Walvax Biotechnology, Fosun Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Nucleic Acid Vaccine Market Report Segments:
The global Nucleic Acid Vaccine market is segmented on the basis of:
Types
Preventive Nucleic Acid Vaccine, Therapeutic Vucleic Acid Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Moderna
- CureVac
- Inovio
- Sanofi
- GSK
- CNBG
- Hualan Bio
- Zhifei Shengwu
- Liaoning Chengda
- BioKangtai
- CanSinoBIO
- Walvax Biotechnology
- Fosun Pharma
Highlights of The Nucleic Acid Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Preventive Nucleic Acid Vaccine
- Therapeutic Vucleic Acid Vaccine
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nucleic Acid Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A nucleic acid vaccine is a vaccine that uses genetic material from a virus or other pathogen to help the body build immunity. This type of vaccine helps protect people against diseases caused by viruses, such as the flu, HPV (human papillomavirus), and measles.
Some of the major players in the nucleic acid vaccine market are Moderna, CureVac, Inovio, Sanofi, GSK, CNBG, Hualan Bio, Zhifei Shengwu, Liaoning Chengda, BioKangtai, CanSinoBIO, Walvax Biotechnology, Fosun Pharma.
The nucleic acid vaccine market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nucleic Acid Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nucleic Acid Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nucleic Acid Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nucleic Acid Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nucleic Acid Vaccine Market Size & Forecast, 2020-2028
4.5.1 Nucleic Acid Vaccine Market Size and Y-o-Y Growth
4.5.2 Nucleic Acid Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Preventive Nucleic Acid Vaccine
5.2.2 Therapeutic Vucleic Acid Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nucleic Acid Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nucleic Acid Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Preventive Nucleic Acid Vaccine
9.6.2 Therapeutic Vucleic Acid Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Preventive Nucleic Acid Vaccine
10.6.2 Therapeutic Vucleic Acid Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Preventive Nucleic Acid Vaccine
11.6.2 Therapeutic Vucleic Acid Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Preventive Nucleic Acid Vaccine
12.6.2 Therapeutic Vucleic Acid Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Preventive Nucleic Acid Vaccine
13.6.2 Therapeutic Vucleic Acid Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nucleic Acid Vaccine Market: Competitive Dashboard
14.2 Global Nucleic Acid Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Moderna
14.3.2 CureVac
14.3.3 Inovio
14.3.4 Sanofi
14.3.5 GSK
14.3.6 CNBG
14.3.7 Hualan Bio
14.3.8 Zhifei Shengwu
14.3.9 Liaoning Chengda
14.3.10 BioKangtai
14.3.11 CanSinoBIO
14.3.12 Walvax Biotechnology
14.3.13 Fosun Pharma
